Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/11/2020 02/12/2020 02/13/2020 02/14/2020 02/18/2020 Date
151.99(c) 151.09(c) 150.09(c) 150.13(c) 149.14(c) Last
3 715 389 5 167 069 5 480 225 5 716 549 7 231 010 Volume
+0.09% -0.59% -0.66% +0.03% -0.66% Change
More quotes
Financials (USD)
Sales 2020 85 861 M
EBIT 2020 27 634 M
Net income 2020 19 976 M
Finance 2020 322 M
Yield 2020 2,69%
Sales 2021 90 138 M
EBIT 2021 30 022 M
Net income 2021 22 921 M
Finance 2021 3 988 M
Yield 2021 2,81%
P/E ratio 2020 20,2x
P/E ratio 2021 17,1x
EV / Sales2020 4,57x
EV / Sales2021 4,31x
Capitalization 393 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
02/24Ex-dividend day for
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
02/18JOHNSON & JOHNSON : MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATION..
AQ
02/18Sanofi to Work on Coronavirus Vaccine
DJ
02/18JOHNSON & JOHNSON : Expands Partnership With HHS to Find Coronavirus Treatment
DJ
02/18JOHNSON & JOHNSON : to Expand Partnership with U.S. Department of Health & Human..
PU
02/1421 States Reject $18 Billion Offer From Drug Wholesalers to Settle Opioid Lit..
DJ
02/14Carney says business must come clean quickly on climate
RE
02/13BY THE NUMBERS : 5 Ways Johnson & Johnson Is Helping Support Coronavirus Relief ..
AQ
02/12JOHNSON & JOHNSON : to Participate in the 9th Annual SVB Leerink Global Healthca..
PR
02/11JOHNSON & JOHNSON : J&J's Janssen to Work With HHS on Accelerating Coronavirus V..
DJ
02/11JOHNSON & JOHNSON : Announces Collaboration with U.S. Department of Health & Hum..
PR
02/07JOHNSON & JOHNSON : Hit with $750M Punitive Damages Verdict for Failing to Warn ..
PR
02/06JOHNSON & JOHNSON : N.J. Jury Orders J&J to Pay $750 Million in Punitive Damages..
DJ
02/06JOHNSON & JOHNSON : Correction to Johnson & Johnson Talc Case Article
DJ
02/06JOHNSON & JOHNSON : Ordered to Pay $750 Million in NJ Talc Case, Bloomberg Repor..
DJ
02/05Drugmakers see long road ahead in coronavirus vaccine race
RE
More news
News in other languages on JOHNSON & JOHNSON
02/14J&J : nouvelles données positives pour l'Ustekinumab
02/09Coronavirus und die Börsen
02/07'BABY POWDER'-KLAGEN : Weitere hohe Strafe gegen Johnson & Johnson
02/07Johnson & Johnson soll Dreiviertelmilliarde zahlen - Berufung eingelegt
02/07Pharmabranche - Vorerst kein Coronavirus-Impfstoff
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
02/18GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
02/18LIVESTOCK HIGHLIGHTS : Top Stories of the Day
DJ
02/18PFIZER : Gets European Approval for Vyndaqel in ATTR-CM
DJ
02/18Sanofi to Work on Coronavirus Vaccine
DJ
02/18Sanofi teams up with U.S. agency against coronavirus
RE
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 160,00  $
Last Close Price 149,14  $
Spread / Highest target 16,0%
Spread / Average Target 7,28%
Spread / Lowest Target -10,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.92%392 517
ROCHE HOLDING AG8.47%299 201
NOVARTIS4.05%220 283
MERCK AND COMPANY-9.33%209 942
PFIZER-6.81%200 999
NOVO NORDISK AS12.78%150 539